| 引用本文: | 胡涵硕,王卓,刘晓东.基于CiteSpace和VOSviewer的吸入性三联药物治疗慢性阻塞性肺疾病的文献计量学分析[J].中国现代应用药学,2023,40(16):2306-2314. |
| HU Hanshuo,WANG Zhuo,LIU Xiaodong.Bibliometric Analysis of Inhaled Triple Drug Therapy for Chronic Obstructive Pulmonary Disease Based on CiteSpace and VOSviewer[J].Chin J Mod Appl Pharm(中国现代应用药学),2023,40(16):2306-2314. |
|
| 摘要: |
| 目的 通过对慢性阻塞性肺疾病(chronic obstructive pulmonary disease，COPD)吸入性三联药物进行文献计量学分析，探索2000年以来三联药物领域的研究热点和研究趋势。方法 基于CiteSpace和VOSviewer软件，对Web of Science核心合集数据库进行检索，将筛选所得文献的年度发文量、作者、机构、期刊和关键词等进行可视化分析，并对机构的聚类情况、关键词的时间线和突显年份进行探讨。结果 2000—2022年COPD吸入性三联药物相关文献发表量为403篇，总体呈增长趋势，主要集中在美国、英国、意大利、德国和加拿大等国；发文量前5名的作者为SINGH D、LIPSON D、MARTINEZ F、DORINSKY P和ISMAILA A，与发文量前5位的研究机构GlaxoSmithKline、AstraZeneca、The University of Manchester、University of Pennsylvania和McMaster University相互吻合，机构间合作密切；COPD病理生理学、三联药物与相关临床试验、药物吸入器技术与种类等是COPD吸入性三联药物领域研究的热点与重点方向；单吸入器三联疗法、多吸入器三联疗法、患者生存率、治疗有效性是三联药物的前沿研究内容。结论 2014年以来COPD的吸入性三联药物越来越受到重视，疾病的病理生理学、三联药物临床试验与主要结局指标、吸入器技术是该领域研究热点，单吸入器三联疗法是该领域前沿研究方向。中国相关研究层次深度与国际影响力有待进一步提升。 |
| 关键词: 慢性阻塞性肺疾病 吸入性三联药物 Web of Science CiteSpace VOSviewer 文献计量学 |
| DOI：10.13748/j.cnki.issn1007-7693.20223026 |
| 分类号: |
| 基金项目:中国医科大学附属盛京医院2020盛京345人才计划(M0723) |
|
| Bibliometric Analysis of Inhaled Triple Drug Therapy for Chronic Obstructive Pulmonary Disease Based on CiteSpace and VOSviewer |
|
HU Hanshuo1,2, WANG Zhuo1,2, LIU Xiaodong1,2
|
|
1.Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, China;2.Department of the Second Clinical Pharmacy, School of Pharmacy, China Medical University, Shenyang 110001, China
|
| Abstract: |
| OBJECTIVE To explore the research hotspots and research trends in the field of inhaled triple drugs therapy for chronic obstructive pulmonary disease(COPD) since 2000 by conducting a bibliometric analysis of triple therapy drugs. METHODS Based on CiteSpace and VOSviewer software, the core database of Web of Science was searched, and the annual publication volume, authors, institutions, journals and keywords of the filtered literature were visually analyzed, and the clustering of institutions and the timeline of keywords were analyzed. Discuss with the highlighted year. RESULTS From 2000 to 2022, the number of publications related to COPD inhaled triple therapy drugs was 403, showing an overall increasing trend, mainly in the United States, the United Kingdom, Italy, Germany, Canada and other countries; the top 5 authors with the number of published papers were SINGH D, LIPSON D, MARTINEZ F, DORINSKY P and ISMAILA A, which were consistent with GlaxoSmithKline, AstraZeneca, The University of Manchester, University of Pennsylvania and McMaster University, the top 5 research institutes with the largest number of publications. Related clinical trials, drug inhaler technology and types were the hot spots and key directions of research in the field of inhaled triple drugs therapy for COPD; single-inhaler triple therapy, multi-inhaler triple therapy, patient survival rate, and treatment effectiveness were the frontiers of triple therapy research content. CONCLUSION Since 2014, inhaled triple-drug therapy for COPD has received more and more attention. The pathophysiology of the disease, clinical trials and main outcome indicators of triple-drug therapy, and inhaler technology are the research hotspots in this field, and single-inhaler triple therapy is the frontier research direction in this field. The depth and international influence of Chinese related research needs to be further improved. |
| Key words: chronic obstructive pulmonary disease inhaled triple therapy drugs Web of Science CiteSpace VOSviewer bibliometrics |
